pus, with concomitantly increased activity of insulin-degrading enzyme at the age of 6 months. However, RAGE deletion could neither prevent the decline in cognitive performance nor the age-related cerebral accumulation of A ␤ peptide. Furthermore, histological analysis revealed no difference in the microglia-occupied brain areas or microglial morphologies between RAGE -/-/arcA ␤ and arcA ␤ mice. Conclusions: Together, our results indicate that while the absence of RAGE was associated with increased insulin-degrading enzyme activity in the brain, it was not sufficient to prevent or ameliorate cognitive deterioration, A ␤ accumulation and microglial activation in the arcA ␤ mouse model of AD.
end products (RAGE), a multiligand receptor belonging to the immunoglobulin superfamily [1] . To determine the phenotype of brain ␤ -amyloidosis in the absence of RAGE, we developed a mouse model, RAGE -/-/arcA ␤ . ArcA ␤ mice, which overexpress the human ␤ -amyloid precursor protein (APP) with both the Swedish and the Arctic mutations, show first cognitive deficits at the age of 6 months [2] . At that age, the animals have abundant A ␤ intracellular punctate deposits in the cortex and hippocampus with no apparent A ␤ plaque load. At 12 months of age, A ␤ plaques and cerebral amyloid angiopathy (CAA) are prominent features. Therefore, we analyzed the RAGE -/-/arcA ␤ mice at 6 and 12 months of age, and tested their cognitive abilities, biochemical and histopathological changes, including brain A ␤ levels, plaque load, CAA and microglial morphology. RAGE -/-/arcA ␤ animals showed significantly lower levels of SDS-and formic-acid-extractable A ␤ in the cortex and hippocampus presumably related to concomitant increases in insulin-degrading enzyme (IDE) activity, as compared with arcA ␤ mice at the age of 6 months. However, these differences did not result in better cognitive performance and were no longer detectable 6 months later when massive A ␤ accumulation occurs.
Materials and Methods
Animals RAGE knockout (RAGE -/-) mice [3] were crossed with arcA ␤ mice [2] to generate the RAGE -/-/arcA ␤ mouse model. The arcA ␤ model is based on the overexpression of human APP 695 with the Swedish (K670N/M671L) and the Arctic (E693G) mutations in a single construct under the control of the prion protein promoter. There were 4 genotypes investigated in parallel: RAGE -/-/ arcA ␤ mice, their respective RAGE -/-littermates, arcA ␤ and their respective wild-type littermates. Six-and 12-month-old mice, 8-9 animals per genotype and age, were analyzed. Each animal group was balanced for gender. The mice were kept under standard housing conditions and a reversed 12-hour light/dark cycle, with free access to food and water. The animal experiments were approved by the Cantonal Veterinary Authority of Zurich. The abrogation of RAGE expression in RAGE -/-animals was demonstrated by Western blot of lung tissue, both directly by detecting no RAGE signal and indirectly by demonstrating reporter EGFR expression (online supplementary fig. 1 , www. karger.com/doi/10.1159/000261723).
Y Maze
The spontaneous alternation rate was assessed using a Yshaped plastic maze, with 40 ! 20 ! 10 cm arm sizes. During 5-min sessions, the sequences of arm entries were recorded; alternation was defined as successive entries into 3 arms, in overlapping triplet sets. The percent alternation was calculated as the ratio of actual to possible alternations (defined as the total number of arm entries -2) ! 100%. The behavioral testing was performed in the dark phase.
Tissue Preparation
Within 1 week of Y maze testing the mice were anesthetized with ketamine-xylazine cocktail (10 mg/kg, i.p.) and flush-perfused transcardially with ice-cold phosphate-buffered saline. Brains were rapidly removed and divided sagittally. One hemibrain was postfixed in phosphate-buffered 4% paraformaldehyde and paraffin-embedded; the other hemibrain was dissected into cortex, hippocampus and cerebellum snap-frozen and stored at -80 ° C for protein analysis.
Histology
Five-micrometer-thick sagittal sections were cut with a Leica RM 2135 microtome. The sections were pretreated with citrate buffer (20 min in microwave at 85 ° C) followed by 95% formic acid (FA) [(5 min at room temperature (RT)], and blocked with 4% bovine serum albumin, 5% goat serum and 5% horse serum at RT for 1 h. The sections were subsequently incubated with primary antibodies overnight at 4 ° C at the following dilutions: mouse 6E10 (1: 500); rabbit anti-Iba1 (1: 500). Secondary fluorophoreconjugated antibodies were used for 2 h at RT. Thioflavin S staining was done according to standard protocol. Automated plaque and microglia counting was performed on 6 sections from each animal, spaced 50 m apart, using the software Image J (http:// rsb.info.nih.gov/ij/). The measurements were limited to the cortex, which was analyzed in the frontal and parietal regions, and the hippocampus.
Three-Step A ␤ Extraction Protocol
Cortices were homogenized in 10 tissue volumes (w/v) of 1% Triton X-100 buffer (50 m M of Tris-HCl, pH 8.0/1% Triton X-100/ complete protease inhibitor cocktail, Roche) with Teflon glass homogenizer (40 strokes) and subsequently centrifuged at 100,000 g for 1 h at 4 ° C. The supernatant was retained as the 1% Triton X-100 soluble fraction. The resulting pellet was homogenized in 10 tissue volumes (w/v) of 2% SDS buffer (50 m M of Tris-HCl, pH 8.0/2% SDS/2 m M EDTA/complete protease inhibitor cocktail EDTA-free, Roche) and centrifuged at 100,000 g for 1 h at 8 ° C. The ensuing supernatant was collected as the 2% SDS soluble fraction. Given the small amount of tissue obtained per hemibrain, mouse hippocampi were homogenized in 10 tissue volumes (w/v) of 1% Triton X-100, 2% SDS buffer (50 m M of Tris-HCl, pH 8.0/1% Triton X-100/2% SDS/complete protease inhibitor cocktail, Roche) with Teflon glass homogenizer (40 strokes) and subsequently centrifuged at 100,000 g for 1 h at 8 ° C. Two percent SDS pellets from cortices and hippocampi were further extracted with a minimum of 225 l of 70% FA and spun at 100,000 g for 1 h at 8 ° C. The FA supernatant was collected by aspiration, avoiding the surface lipid layer and the acid insoluble bottom pellet. Aliquots of the 70% FA soluble fraction were lyophilized overnight in order to remove the acid and stored at -80 ° C.
Immunoblots
Tissue extracts were separated by SDS-PAGE using 10-20% Tricine gels (Invitrogen) and transferred onto nitrocellulose membranes. After an optional epitope retrieval and blocking in 5% milk TBS-T, the membranes were probed with 6E10 (1: 500, Signet), 22C11 (1: 1,000, Chemicon International), anti-APP C-terminal (1: 4,000, Sigma), anti-mouse/rat RAGE (1: 500, R&D Systems; 1: 1,000 rabbit polyclonal antibodies against RAGE V, C1 and C2 domains [4] ) and anti-GFP (1: 1,000, Roche) antibodies. Immunopositive bands were visualized by chemiluminescence (ECL, Amersham Biosciences) and subsequently quantified by densitometric analysis of their intensity levels. ␤ -Tubulin was used as loading control (1: 10,000, Sigma). The results were expressed as signal intensities normalized to values pertaining to arcA ␤ animals.
A ␤ 40 and A ␤ 42 ELISA of Cerebral A ␤ The A ␤ 40 and A ␤ 42 quantities in the above-mentioned fractions were determined using hAmyloid ␤ 40 and hAmyloid ␤ 42 ELISA kits (The Genetics Company AG, Switzerland).
Enzymatic Assays
Cortical tissue from 4 mice per genotype was pooled. The pooled tissue was homogenized in a 4-fold (w/v) volume of 20 m M Tris-HCl (pH 7.4), 0.5% Triton X-100, 10 M PMSF. Homogenate was centrifuged at 13,000 rpm for 15 min at 4 ° C. Supernatant was used as a sample for the assay. The protein concentration was determined with the BCA Protein Assay (Pierce) and measured against bovine serum albumin standards.
IDE Activity Assay. The IDE activity in the supernatant was determined with the fluorometric Innozyme Insulysin/IDE Immunocapture Activity Assay Kit (Calbiochem, Merck) according to the manufacturer's instructions. The reaction time was 1 h. The IDE activity was expressed in nanograms/milliliter of crude cortical homogenates that were normalized to 2 mg/ml protein concentration.
Angiotensin-Converting Enzyme Activity Assay. The angiotensin-converting enzyme (ACE) activity in the supernatant against the synthetic substrate N-hippuryl-L -histidyl-L -leucine was determined using an ACE colorimetric kit (Buhlmann Laboratories AG, Schönenbuch, Switzerland). The reaction time was 3 h.
Neprilysin Activity Assay. The neprilysin enzyme activity was measured as described previously [5, 6] , using a fluorometric assay for the generation of free dansyl-D-Ala-Gly (DAG) from Ndansyl-Ala-Gly-D-nitro-Phe-Gly (DAGNPG; Sigma), a fluorogenic substrate for neprilysin. Substrate solutions containing 1 m M of DAGPNG and 10 M of enalapril (Sigma) in 20 m M of Tris HCl with and without the addition of 10 M of NEP inhibitor phosphoramidon were prepared and preincubated at 37 ° C for 10 min. Enalapril, an ACE inhibitor, was added to prevent ACE-mediated DAGNPG cleavage. Fifty micorliters of the sample were incubated for 1 h with 100 l of each substrate solution. The reaction was stopped by boiling for 10 min at 90 ° C. The samples were then spun for 5 min at 10,000 rpm. The fluorescence of the supernatants was measured at an emission wavelength of 562 nm and an excitation wavelength of 342 nm. The NEP activity was calculated as a difference in fluorescence between samples incubated with and without phosphoramidon, and expressed as relative fluorescence units.
Statistical Analysis
The data were analyzed using SPSS 14.0 (SPSS Inc., Chicago, Ill., USA). Differences between the means were assessed by Student's t test or 1-way ANOVA followed by Fisher's LSD or Tukey's post-hoc tests. Correlation studies were performed by parametric correlation and linear regression analysis. The null hypothesis was rejected at the 0.05 level.
Results

Absence of RAGE Reduced the Amount of Insoluble A ␤ in 6-Month-Old ArcA ␤ Mice
In order to evaluate the influence of RAGE deletion (online suppl. fig. 1 ) on A ␤ deposition, we examined the A ␤ peptide levels in the brain regions relevant to cognition, i.e. the hippocampus and cortex. The A ␤ levels were assessed with respect to the extraction conditions and the variant length (A ␤ 40 and A ␤ 42) using Western blot and C-terminus-specific ELISA. The brains were extracted sequentially in 1% Triton X-100, 2% SDS and 70% FA, to allow for the isolation of A ␤ species that differ in the aggregation state and cellular/extracellular localization, with SDS-extractable A ␤ pertaining to the membraneenriched fraction and FA-extractable (insoluble) A ␤ representing extracellular amyloid. Both the Western blot and ELISA approaches indicated significantly lower overall levels of accumulated A ␤ in the cortex and hippocampus at the age of 6 months in RAGE -/-/arcA ␤ animals compared to arcA ␤ mice with normal RAGE expression. Interestingly, the difference was due to the low A ␤ levels extracted into SDS and FA, but not caused by Triton X-100-requiring peptide ( tables 1 and 2 ). Despite the clear differences in the amount of extractable A ␤ found by biochemical methods, histological analysis did not reveal any difference in A ␤ -occupied brain areas at 6 months ( fig. 1 a) , possibly due to the fact that at this age, visible plaque formation has not yet started in arcA ␤ mice [2] . At the age of 12 months, when A ␤ deposition has progressed much more, biochemical and histopathological approaches revealed no more difference in the total A ␤ load, nor A ␤ 40 and A ␤ 42 variants, in any of the fractions between RAGE -/-/arcA ␤ and arcA ␤ mice ( tables 1 and 2 ; fig. 1 b) . However, the A ␤ 40 level was significantly decreased in the serum of RAGE -/-/arcA ␤ animals. Given the possibility that the genetic manipulation might not only influence A ␤ deposition and quantities but also morphological features of deposits, we examined both plaques and CAA but found no structural differences between RAGE -/-/arcA ␤ and arcA ␤ mice ( fig. 2  and 3 ). Plaques in RAGE -/-/arcA ␤ animals, detected at 12 months ( fig. 3 a, g ), had the same dense-core morphology as arcA ␤ mice ( fig. 3 b, d , h, j) and were also accompanied by severe CAA ( fig. 3 c, i) .
RAGE Did Not Influence APP Expression and Processing
To determine whether the decreased amount of A ␤ could be due to altered APP expression or processing caused by the absence of RAGE, we examined the levels of full-length APP (APP), soluble APP (sAPP) as well as C-terminal fragments produced by ␤ -secretase (CTF-␤ ) by Western blot using 6E10, 22C11 and anti-APP C-terminal antibodies. There was no difference in APP, sAPP and CTF-␤ levels according to the densitometric analysis of immunoblots upon normalization to ␤ -tubulin in the cortex and the hippocampus between the 2 transgenic groups ( fig. 4 ) .
RAGE
-/-/ArcA ␤ Mice Showed Increased A ␤ -Degrading Enzymatic Activity Our finding that the cerebral levels of SDS-and FAsoluble A ␤ were reduced in the brains of 6-month-old mice without any change in APP processing suggested that the activity of 1 or more A ␤ -degrading proteases might be increased. To test this hypothesis, we examined the enzymatic activity of 3 proteases in the cortices of 6-and 12-month-old animals. Analysis of IDE activity re- fig. 5 a) . However, at the age of 12 months the difference between RAGE -/-/arcA ␤ and arcA ␤ was not statistically significant; RAGE -/-/arcA ␤ animals had an increased activity of the enzyme only in comparison with the wild-type animals (p = 0.043). There was no significant difference in the activity of 2 other A ␤ -degrading enzymes, ACE and neprilysin, among the 4 groups ( fig. 5 b, c) .
Absence of RAGE Did Not Ameliorate Cognitive Impairment
To clarify whether the reduced amount of A ␤ in RAGE -/-/arcA ␤ mice at 6 months would result in less se- vere cognitive deficits that had previously been described in arcA ␤ mice, the different genotype groups were tested in the Y maze, a working memory test. There was no significant difference in Y maze performance between the RAGE -/-/arcA ␤ and arcA ␤ animal groups at the age of 6 and 12 months. Although they had less SDS-and FAsoluble A ␤ load at 6 months, the RAGE -/-/arcA ␤ mice had the same extent of cognitive deficits as the arcA ␤ animals. This impairment was not due to the lack of RAGE, since the RAGE -/-mice performed equally well as the wild-type animals ( fig. 6 ).
Cognitive Impairment Correlated with
Triton-X-Extractable A ␤ Given the cognitive deficits in the animals harboring the APP transgene, we evaluated whether the extent of accumulated A ␤ was related to the degree of cognitive performance in individual mice. There was a significant negative correlation between the percent alternation in the Y maze and monomeric A ␤ cortical levels present in 1% Triton X-100 fraction determined by densitometric analysis of Western blot with 6E10 antibody but not with the A ␤ levels in other fractions or in the hippocampus. Additionally, there was no significant correlation between Y-maze performance and the levels of 2 length variants, A ␤ 40 or A ␤ 42. The association between soluble A ␤ load in the cortical area and working memory impairment was significant at the age of 6 months for both RAGE -/-/arcA ␤ (p = 0.0146) and arcA ␤ mice (p = 0.043) ( fig. 7 a) , and the r values obtained for the 2 groups were not significantly different. At 12 months of age, the negative correlation was only significant for the RAGE -/-/ arcA ␤ mice (p = 0.020; fig. 7 b) . ␤ ( b , d , f , h , j ) . a-d 6E10 staining (green), paralleled with the Iba1 staining of microglia [31] , revealing plaque morphology ( a , b ) and CAA ( c , d ). e-j Thioflavin-S-stained overview images of mouse cortices ( e , f ) and their respective enlarged details demonstrating dense-core plaques ( g , h ) and CAA ( i , j ). Scale bar: 100 m ( e , f ); 50 m ( a-d , g-j ) . 
Lack of RAGE Did Not Alter the Amount of Microglia
No difference in the microglia-occupied brain area or microglial morphology was observed in RAGE -/-mice in comparison to wild-type animals at both examined ages ( fig. 8 c, d) . Also, these animals did not differ from RAGE -/-/arcA ␤ and arcA ␤ mice with respect to the microglia-occupied brain area at the age of 6 months, when no dense-core plaques or CAA can be demonstrated yet ( fig. 8 a) . At 12 months, there was a significant equal increase in Iba1-occupied brain area in both RAGE -/-/ arcA ␤ and arcA ␤ mice when compared to APP nontransgenic animals ( fig. 8 b) , due to the formation of plaques and CAA that attract microglia ( fig. 4 a-d) .
Discussion
Several lines of evidence suggested a role of the RAGE receptor in AD pathogenesis with different underlying processes proposed. Studies in mice and cell culture indicated that RAGE promotes A ␤ accumulation through 2 different mechanisms. First, RAGE is thought to mediate A ␤ peptide influx into the central nervous system through the blood-brain barrier [7, 8] , thus increasing the amount of A ␤ in the brain. The second mechanism leading to enhanced A ␤ accumulation via RAGE proposes a direct stimulation of BACE1 expression, the secretase involved in A ␤ production [9] . In addition, RAGE is assumed to promote AD pathology by activating microglia, with subsequent induction of chemotaxis, cell proliferation, as well as ROS and cytokine production [1, 10, 11] . To better understand the in vivo role of RAGE in AD pathology, we generated and characterized arcA ␤ mice lacking RAGE. These animals had an increased IDE activity during the first 6 months of life and were protected from A ␤ accumulation only to a certain extent. There were lower levels of A ␤ extractable by SDS and FA (insoluble A ␤ ) in the brains of RAGE -/-/arcA ␤ mice at the age of 6 months, but this effect disappeared by the age of 12 months, most probably due to the constant peptide production overwhelming the clearance process. In addition, the observed IDE upregulation resulted from an additive effect of RAGE deletion and the APP transgene or probably A ␤ accumulation, as previously suggested [12, 13] . Although it presumably decreased initial A ␤ buildup, the IDE-mediated clearance process did not prevent cognitive decline and eventually became inefficient at the age of 12 months given the similar amounts of cerebral A ␤ in both genotypes. ArcA ␤ mice have been previously shown to generate A ␤ only in the nervous system [2] , thus precluding the relevance of external A ␤ influx into the brain to the development of brain pathology in this mouse model. In addition, our study showed significantly lower serum levels of A ␤ 40 in RAGE -/-/arcA ␤ mice than in the arcA ␤ animals at the age of 12 months, contradicting the possible relevance of A ␤ transport across the blood-brain barrier for cerebral A ␤ accumulation. RAGE involvement in APP processing via BACE did not seem to be plausible in the arcA ␤ mice either given the identical levels of CTF-␤ observed in both genotypes. Similarly, our study did not reveal any change in microglia number or morphology in animals lacking RAGE. The RAGE -/-/ arcA ␤ mice had comparable brain areas occupied by microglia in both age groups. Additionally, there was a marked activation of microglia evident in parallel with the onset of fibrillar plaques in both genotypes, which would not favor an in vivo role of RAGE to promote microglia activation in AD either. This is in agreement with the previous findings in APP23 mice, whereby the majority of activated microglia, present in the vicinity of amyloid plaques, did not upregulate RAGE expression [14] .
Differences observed between previous studies and the results presented here may be explained by confounding factors not accounted for in previously applied experimental settings, methodologies and animal models. These include APP transgenic mice overexpressing RAGE or bearing dominant-negative RAGE (DN-RAGE), DN-RAGE and wild-type mice injected or infused with A ␤ , as well as APP transgenic or A ␤ -infused mice which were treated with truncated, soluble form of RAGE, sRAGE [7, 15, 16] . Remarkably, sRAGE-treated animals show greater protection compared to RAGE-null (RAGE -/-) animals against deleterious effects of inflammation [17] , diabetic nephropathy and concomitant VEGF expression [18] , or diabetic neuropathy [19] , conditions in which RAGE is suggested to be a key pathology-mediating molecule. In addition, exogenous sRAGE blocks inflammation even in RAGE -/-animals [17] , which altogether suggests involvement of sRAGE in additional pathways linked to inflammatory response. Endogenous sRAGE is produced by alternative splicing of the RAGE mRNA as well as by proteolytic cleavage [20, 21] . According to the studies conducted with exogenous sRAGE, endogenous sRAGE was supposed to play an antagonistic role by competing with cell surface RAGE, thus inhibiting RAGEinduced signaling [7, 17, 22] . The physiologic concentrations of circulating sRAGE, found in diabetic patients, are much lower than required to scavenge accumulating ligands [23] . It is, however, possible that RAGE and DN-RAGE overexpression [15] leads to increased levels of sRAGE with protective properties. Additionally, mechanisms accounting for the absence of pathological effects in APP mice expressing DN-RAGE could be similar to the more overt protection observed in DN-RAGE mice compared to RAGE -/-animals in the context of atherosclerosis [24] .
No reduction in A ␤ levels was observed in Triton X-100 brain extract, the only A ␤ fraction correlating with Y maze performance. Such a correlation is in line with the previous AD research pointing to the causative role of A ␤ oligomers present in the soluble brain extracts [25, 26] . At the age of 12 months, when the A ␤ load increased in all fractions in both genotypes, such a correlation was not detected in arcA ␤ mice, possibly because of different susceptibility to soluble A ␤ in this group of animals. The same extent of cognitive impairment observed in RAGE -/-/arcA ␤ mice as in arcA ␤ mice is also challenging the hypothesis about RAGE contribution to brain A ␤ -related pathophysiology. This is consistent with the recent study investigating a relationship between the psychomotor or cognitive performance and amounts of RAGE increasing with age in several brain regions which failed to detect any association between the variables [27] . Moreover, in the same study there was no correlation between the age-related accumulation of advanced glycation end products, which are major RAGE ligands, and RAGE expression in the mouse brain. Another report about enhanced A ␤ deposition in the mouse brain did not find any parallel significant change in RAGE expression [28] .
The observed significant upregulation of IDE in RAGE -/-/arcA ␤ mice at the age of 6 months suggested that IDE expression and RAGE signaling function are associated. The underlying network linking the 2 molecules has not been unraveled. Recently, it has been described that while the 'anti-inflammatory' cytokines IL-4 and IL-13 increase IDE expression [29] , 'pro-inflammatory' IFN-␥ and TNF-␣ have an opposite effect [30] . Deletion of RAGE and removal of its proinflammatory influence may thus push the balance towards the anti-inflammatory pathways and promote IDE expression. In conclusion, a general contribution of RAGE to microglial activation, A ␤ intracerebral accumulation or cognitive impairment in the arcA ␤ mice seems to be unlikely. The initial increase in IDE activity, however, along with the reduced brain A ␤ levels during the initial 6 months of life may permit an unexpected role of RAGE in regulating A ␤ proteolysis.
